MCID: OPT009
MIFTS: 56

Optic Neuritis

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Optic Neuritis

MalaCards integrated aliases for Optic Neuritis:

Name: Optic Neuritis 12 74 52 36 54 6 43 15 17 71 32

Classifications:



External Ids:

Disease Ontology 12 DOID:1210
KEGG 36 H01717
ICD9CM 34 377.3 377.30
MeSH 43 D009902
NCIt 49 C84950
SNOMED-CT 67 66760008
ICD10 32 H46 H46.9
UMLS 71 C0029134

Summaries for Optic Neuritis

KEGG : 36 Optic neuritis is a demyelinating inflammatory disease of the optic nerve that presents with an abrupt loss of vision. The majority of patients are between the ages of 20 and 50 years, with a mean age ranging from 30 to 35 years. It occurs more commonly in women than in men. The onset is usually with pain on eye movement in one eye and subacute visual loss. One-third of patients have a mildly edematous optic disc. The visual disturbance resolves in 95% of cases. Many cases of optic neuritis are associated with multiple sclerosis or neuromyelitis optica or can occur in isolation. Occasionally, optic neuritis can result from infectious processes involving the paranasal sinuses or occur in the course of a systemic viral infection. High-dosed intravenous methylprednisolone therapy speeds recovery but does not improve the final outcome. For patients judged to be at high risk of developing multiple sclerosis, immune prophylaxis with beta-interferon or glatiramer acetate is recommended.

MalaCards based summary : Optic Neuritis is related to autoimmune optic neuritis and nutritional optic neuropathy, and has symptoms including eye manifestations An important gene associated with Optic Neuritis is AQP4 (Aquaporin 4), and among its related pathways/superpathways are PEDF Induced Signaling and Akt Signaling. The drugs Bevacizumab and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include optic nerve which may cause a complete, eye and brain, and related phenotypes are behavior/neurological and cellular

Disease Ontology : 12 An optic nerve disease that results in inflammation located in optic nerve which may cause a complete or partial loss of vision.

NIH Rare Diseases : 52 Optic neuritis is inflammation of the optic nerve, the nerve that carries the visual signal from the eye to the brain. The condition may cause sudden, reduced vision in the affected eye(s). While the cause of optic neuritis is unknown, it has been associated with autoimmune diseases , infections, multiple sclerosis , drug toxicity and deficiency of vitamin B-12. Vision often returns to normal within 2-3 weeks without treatment. In some cases, corticosteroids are given to speed recovery. If known, the underlying cause should be treated.

Wikipedia : 74 Optic neuritis is a demyelinating inflammation of the optic nerve. It is also known as optic papillitis... more...

Related Diseases for Optic Neuritis

Diseases in the Optic Neuritis family:

Autoimmune Optic Neuritis

Diseases related to Optic Neuritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 709)
# Related Disease Score Top Affiliating Genes
1 autoimmune optic neuritis 34.2 MOG MBP DPYSL5 CNTF AQP4
2 nutritional optic neuropathy 33.3 MT-ND4 DPYSL5
3 neuromyelitis optica 33.2 MOG MBP HLA-DRB1 GFAP CXCL10 AQP4
4 allergic encephalomyelitis 32.0 PLP1 MOG MBP
5 optic nerve disease 31.7 TNF MT-ND6 MT-ND4 MOG MBP GFAP
6 scotoma 31.6 MT-ND6 MT-ND4 AQP4
7 acute retrobulbar neuritis 31.6 MT-ND4 MBP AQP4
8 optic papillitis 31.6 MOG AQP4
9 herpes zoster 31.2 TNF IL10 HLA-DRB1 CCR5
10 rubella 31.2 TNF MOG IL10 HLA-DRB1
11 meningoencephalitis 31.1 TNF MBP IL10 BDNF
12 transverse myelitis 31.1 TNF MBP IL10 CXCL8 AQP4
13 meningitis 31.0 TNF IL10 CXCL8 AQP4
14 exanthem 31.0 TNF IL10 CXCL8
15 acquired immunodeficiency syndrome 31.0 TNF MBP IL10 CCR5
16 panuveitis 30.9 TNF IL10 HLA-DRB1
17 guillain-barre syndrome 30.9 TNF MPZ MOG MBP HLA-DRB1
18 myelitis 30.9 TNF MOG MBP IL10 DPYSL5 CXCL8
19 acute disseminated encephalomyelitis 30.9 MPZ MOG MBP IL10 HLA-DRB1 DPYSL5
20 neurosyphilis 30.9 IL10 CXCL8 CXCL10
21 typhoid fever 30.8 TNF LTA HLA-DRB1
22 cytomegalovirus retinitis 30.8 TNF IL10 HLA-DRB1 CCR5
23 internuclear ophthalmoplegia 30.8 MOG AQP4
24 spondylitis 30.8 TNF LTA IL10
25 wallerian degeneration 30.8 MPZ MAG CNTF
26 aseptic meningitis 30.8 TNF IL10 CXCL8
27 multifocal choroiditis 30.8 TNF IL10
28 pediatric multiple sclerosis 30.7 MOG HLA-DRB1
29 chronic inflammatory demyelinating polyradiculoneuropathy 30.7 MPZ MBP IL10 HLA-DRB1
30 myasthenia gravis 30.7 TNF PLP1 MBP LTA IL10
31 hepatitis a 30.7 TNF IL10 CXCL10
32 intracranial hypertension 30.6 TNF CXCL10 AQP4
33 mononeuropathy 30.6 TNF MPZ MAG
34 subacute sclerosing panencephalitis 30.6 TNF MOG MBP IL10
35 tetanus 30.6 TNF MBP LTA IL10
36 polyneuropathy 30.6 TNF MPZ MBP MAG CNTF
37 crohn's disease 30.6 TNF IL10 HLA-DRB1 CXCL8
38 encephalitis 30.6 TNF MOG IL10 GFAP CXCL10 CCR5
39 toxoplasmosis 30.6 TNF IL10 CCR5
40 colitis 30.5 TNF IL10 HLA-DRB1 CXCL8
41 mumps 30.5 TNF IL10 HLA-DRB1 CXCL8 CXCL10
42 ulcerative colitis 30.5 TNF IL10 HLA-DRB1 CXCL8
43 keratitis, hereditary 30.5 TNF IL10 CXCL8
44 chlamydia 30.5 TNF IL10 CXCL8
45 churg-strauss syndrome 30.4 TNF IL10 CXCL8
46 osteomyelitis 30.4 TNF IL10 CXCL8 CXCL10
47 polyradiculoneuropathy 30.4 MPZ MBP MAG IL10 HLA-DRB1
48 sarcoidosis 1 30.4 TNF LTA HLA-DRB1 CXCR3 CXCL10 CCR5
49 spondyloarthropathy 30.4 TNF LTA IL10
50 brucellosis 30.3 TNF IL10 CXCL8

Comorbidity relations with Optic Neuritis via Phenotypic Disease Network (PDN):


Hypertension, Essential Temporal Arteritis

Graphical network of the top 20 diseases related to Optic Neuritis:



Diseases related to Optic Neuritis

Symptoms & Phenotypes for Optic Neuritis

UMLS symptoms related to Optic Neuritis:


eye manifestations

MGI Mouse Phenotypes related to Optic Neuritis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.28 AQP4 BDNF CCR5 CNTF DPYSL5 GFAP
2 cellular MP:0005384 10.22 BDNF CCR5 CNTF CXCL10 CXCR3 GFAP
3 homeostasis/metabolism MP:0005376 10.2 AQP4 BDNF CCR5 CNTF CXCL10 CXCR3
4 hematopoietic system MP:0005397 10.18 AQP4 CCR5 CNTF CXCL10 CXCR3 IL10
5 immune system MP:0005387 10.1 AQP4 CCR5 CNTF CXCL10 CXCR3 GFAP
6 nervous system MP:0003631 9.86 AQP4 BDNF CCR5 CNTF CXCL10 DPYSL5
7 muscle MP:0005369 9.76 CCR5 CNTF GFAP IL10 MOG MT-ND6
8 vision/eye MP:0005391 9.36 AQP4 BDNF CCR5 GFAP IL10 LTA

Drugs & Therapeutics for Optic Neuritis

Drugs for Optic Neuritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4 216974-75-3
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Levodopa Approved Phase 4 59-92-7 6047
4
Carbidopa Approved Phase 4 28860-95-9 34359
5
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
6
4-Aminopyridine Approved Phase 4 504-24-5 1727
7
Idebenone Approved, Investigational Phase 4 58186-27-9
8
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
9
Choline Approved, Nutraceutical Phase 4 62-49-7 305
10 (T,G)-A-L Phase 4
11
Glatiramer Acetate Phase 4 147245-92-9 3081884
12 Angiogenesis Inhibitors Phase 4
13 Dopamine Agents Phase 4
14 Aromatic Amino Acid Decarboxylase Inhibitors Phase 4
15 Antiparkinson Agents Phase 4
16 Carbidopa, levodopa drug combination Phase 4
17 Dopamine agonists Phase 4
18 Nootropic Agents Phase 4
19 Cytidine Diphosphate Choline Phase 4
20 Potassium Channel Blockers Phase 4
21 Antioxidants Phase 4
22 Adrenocorticotropic Hormone Phase 4
23 Melanocyte-Stimulating Hormones Phase 4
24 beta-endorphin Phase 4
25 Phosphodiesterase 5 Inhibitors Phase 4
26 Phosphodiesterase Inhibitors Phase 4
27 Vardenafil Dihydrochloride Phase 4
28 Sildenafil Citrate Phase 4 171599-83-0
29
Curcumin Approved, Experimental, Investigational Phase 3 458-37-7 969516
30
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
31
Azathioprine Approved Phase 2, Phase 3 446-86-6 2265
32
Ravulizumab Approved, Investigational Phase 3 1803171-55-2
33
Bosentan Approved, Investigational Phase 3 147536-97-8 104865
34
Interferon beta-1b Approved Phase 2, Phase 3 145155-23-3
35 Analgesics, Non-Narcotic Phase 3
36 Anti-Inflammatory Agents, Non-Steroidal Phase 3
37 Analgesics Phase 3
38 Rho(D) Immune Globulin Phase 3
39 Immunoglobulins, Intravenous Phase 3
40 gamma-Globulins Phase 3
41 Complement System Proteins Phase 3
42 Complement Inactivating Agents Phase 3
43 Mastic Phase 3
44 Butylated Hydroxytoluene Phase 3
45 Endothelin Receptor Antagonists Phase 3
46 Hematinics Phase 3
47 Epoetin alfa Phase 3 113427-24-0
48 Pharmaceutical Solutions Phase 3
49 Anesthetics Phase 3
50 Central Nervous System Depressants Phase 3

Interventional clinical trials:

(show top 50) (show all 173)
# Name Status NCT ID Phase Drugs
1 A Multicenter Longitudinal Cross-sectional Pilot Study, to Compare RNFL Thickness Measured by OCT After Treatment With Glatiramer or After no Treatment in Patients With CIS With or Without Optic Neuritis or With Early RRMS Unknown status NCT00910598 Phase 4 glatiramer acetate
2 Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans Completed NCT00312325 Phase 4 Prednisolone
3 Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy Completed NCT00432393 Phase 4 levodopa-carbidopa
4 Dalfampridine Treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Completed NCT01975324 Phase 4 dalfampridine;Placebo
5 Controlled High-risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurologic Surveillance (CHAMPIONS10) Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
6 Phase 4 Study of Evaluation of Neural Conduction Along the Visual Pathways Before and After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases Completed NCT00404729 Phase 4 Cytidine-5’-diphosphocholine (Citicoline)
7 Use of Bevacizumab in Trabeculectomy Surgery. A Prospective, 2 Centre, Randomized, Controlled Trial Completed NCT01166594 Phase 4 Bevacizumab;Control
8 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
9 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Recruiting NCT01838174 Phase 4 ACTHAR Gel (ACTH);IV methylprednisolone (steroids)
10 Short and Long Term Fampridine Treatment in Persons With Multiple Sclerosis: Cognitive and Motor Performances Recruiting NCT02849782 Phase 4 Fampridine
11 External Natural History Controlled, Open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment With Raxone® in Leber's Hereditary Optic Neuropathy (LHON) Active, not recruiting NCT02774005 Phase 4 Idebenone
12 Prospective Case Crossover Study to Assess Whether PDE5 Inhibitor Exposure in Men Increases the Risk for the Development of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Terminated NCT00867815 Phase 4 Diagnostic procedures
13 Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis Terminated NCT00854750 Phase 4 ACTHAR;ACTHAR;ACTHAR;ACTHAR
14 Optical Coherence Tomography as a Measure of Neuroprotection in Patients With Relapsing-Remitting Multiple Sclerosis Receiving Natalizumab or Interferon Beta-1a Withdrawn NCT00771043 Phase 4 TYSABRI and AVONEX
15 An Open Label Pilot Study of Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event: Comparison With CHAMPS Results. Withdrawn NCT00037115 Phase 4 interferon beta 1a;methotrexate;methylprednisolone
16 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: a Pivotal Randomized Double Masked Placebo Controlled Study Unknown status NCT02220244 Phase 3 MD1003 100mg capsule
17 Optic Neuritis Treatment Trial (ONTT) Unknown status NCT00000146 Phase 3 Methylprednisolone;Prednisone
18 Simvastatin Treatment of Patients With Acut Optic Neuritis. A Doubleblind, Randomized and Placebo Controlled Fase III Trial Unknown status NCT00261326 Phase 3 simvastatin;placebo
19 Retrobulbar Triamcinolone Acetonide Injection in the Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy Unknown status NCT02329288 Phase 3 Triamcinolone Acetonide;placebo
20 The Effect of High Dose Steroid and Normobaric Oxygen Therapy on Recent Onset Non-arteritic Anterior Ischemic Optic Neuropathy(NAION); a Randomized Clinical Trial Unknown status NCT02439866 Phase 3 placebo;Intravenous methylprednisolone;normobaric oxygen with face mask
21 Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial Completed NCT01962571 Phase 3 Erythropoietin alfa;Placebo
22 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON) Completed NCT00856635 Phase 3 Glatiramer Acetate;placebo
23 Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis Completed NCT01337986 Phase 2, Phase 3 Dalfampridine/Placebo;Placebo/Dalfampridine
24 Recovery of Demyelinating Optic Neuritis After Treatment With Equivalent High Doses of Oral vs. Intravenous Corticosteroids: a Randomized Single Blinded Clinical Trial Completed NCT01524250 Phase 2, Phase 3 corticosteroids;corticosteroids
25 Intravenous Immunoglobulin Therapy in Optic Neuritis Completed NCT00000117 Phase 3 Immunoglobulin
26 Paraorbital-occipital Alternating Electric Current Stimulation in Patients With Optic Neuropathy Completed NCT01282827 Phase 2, Phase 3
27 A Randomized, Double-blind, Placebo-controlled Trial of Curcumin in Leber's Hereditary Optic Neuropathy (LHON) Completed NCT00528151 Phase 3 curcumin
28 Ischemic Optic Neuropathy Decompression Trial (IONDT) Completed NCT00000127 Phase 3
29 Comparison of Annual Relapse Rate, Expanded Disability Status Scale, and Side Effects Between Azathioprine and Rituximab in Patients With Neuromyelitis Optica Spectrum Disorders Completed NCT03002038 Phase 2, Phase 3 Azathioprine;Rituximab
30 Effects of Dalfampridine on Cognition in Multiple Sclerosis Completed NCT02006160 Phase 2, Phase 3 dalfampridine;placebo
31 A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) Recruiting NCT04201262 Phase 3
32 Traumatic Optic Neuropathy Treatment Trial 2; Efficacy of Different Doses of Erythropoietin. A Multicenter, Double Blind RCT Recruiting NCT03308448 Phase 3 Recombinant human erythropoietin
33 A Double-Masked Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Participants With Previous NAION Recruiting NCT03547206 Phase 3 RPh201
34 Effect of Bosentan in Patients With Non Arteritic Ischemic Optic Neuropathy Recruiting NCT02377271 Phase 3 bosentan;placebo
35 A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO) Active, not recruiting NCT02003144 Phase 3
36 Erythropoietin in Methanol Associated Optic Neuropathy Active, not recruiting NCT02376881 Phase 3 Erythropoietin
37 Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected With G11778A ND4 Leber Hereditary Optic Neuropathy for Up to One Year Active, not recruiting NCT03293524 Phase 3 Placebo
38 Safety and Efficacy Study of Gene Therapy for The Treatment of Leber's Hereditary Optic Neuropathy Active, not recruiting NCT03153293 Phase 2, Phase 3 rAAV2-ND4
39 A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients With Relapsing Neuromyelitis Optica Spectrum Disorder Not yet recruiting NCT04155424 Phase 2, Phase 3 Eculizumab
40 Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic Neuritis Terminated NCT01647880 Phase 2, Phase 3 Verum arm receiving Gilenya®;Active Comparator receiving Extavia®
41 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO) Terminated NCT01892345 Phase 3 Eculizumab;Placebo
42 A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Terminated NCT02341560 Phase 2, Phase 3 QPI-1007 Injection - 1.5 mg;QPI-1007 Injection - 3.0 mg
43 Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON) Withdrawn NCT01495715 Phase 3 Idebenone;Placebo
44 The Investigation Effect of Vitamin D on Retinal Changes in Patient With Optic Neuritis by Optic Coherence Tomography Unknown status NCT01465893 Phase 2 Vitamin D;Vitamin D withheld
45 A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis Unknown status NCT01879527 Phase 2 Amiloride hydrochlorothiazide;Sugar pill
46 Trial of Cyclosporine in the Acute Phase of Leber Hereditary Optic Neuropathy Unknown status NCT02176733 Phase 2 cyclosporine
47 Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
48 Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo in Acute Nonarteritic Anterior Ischemic Optic Neuropathy Unknown status NCT01330524 Phase 1, Phase 2 Avastin and Triamcinolone
49 A Randomised, Double-blind, Placebo-controlled Study of AIMSPRO in Treating Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Unknown status NCT01228396 Phase 2 Hyperimmune caprine serum against HIV lysate
50 Intravitreal Bevacizumab for Treatment of the Second Eye With Non-Arteritic Ischemic Optic Neuropathy Unknown status NCT00813059 Phase 2 Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)

Search NIH Clinical Center for Optic Neuritis

Cochrane evidence based reviews: optic neuritis

Genetic Tests for Optic Neuritis

Anatomical Context for Optic Neuritis

The Foundational Model of Anatomy Ontology organs/tissues related to Optic Neuritis:

19
Optic Nerve Which May Cause A Complete

MalaCards organs/tissues related to Optic Neuritis:

40
Eye, Brain, Testes, Lung, T Cells, Spinal Cord, Bone

Publications for Optic Neuritis

Articles related to Optic Neuritis:

(show top 50) (show all 5376)
# Title Authors PMID Year
1
Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. 54 61
20019228 2010
2
Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. 54 61
19917985 2009
3
Association of the HLA-DPB1*0501 allele with anti-aquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders. 54 61
19140826 2009
4
A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica. 54 61
18509235 2008
5
Neuromyelitis optica pathogenesis and aquaporin 4. 54 61
18510734 2008
6
Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. 54 61
12838519 2003
7
Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. 54 61
12732654 2003
8
Multiple MAG peptides are recognized by circulating T and B lymphocytes in polyneuropathy and multiple sclerosis. 54 61
11985632 2002
9
Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD1a. 54 61
10618693 1999
10
Augmented expression of tumour necrosis factor-alpha and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis. 54 61
8624683 1996
11
Acute optic neuritis: myelin basic protein and proteolipid protein antibodies, affinity, and the HLA system. 54 61
8526468 1995
12
PCR typing of two short tandem repeat (STR) structures upstreams of the human myelin basic protein (MBP) gene; the genetic susceptibility in multiple sclerosis and monosymptomatic idiopathic optic neuritis in Danes. 54 61
9345452 1995
13
Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis. 54 61
7532318 1995
14
Optic neuritis and multiple sclerosis: the T cell repertoires to myelin proteins and MBP peptides change with time. 54 61
7524258 1994
15
Autoimmune T cell repertoire in optic neuritis and multiple sclerosis: T cells recognising multiple myelin proteins are accumulated in cerebrospinal fluid. 54 61
7515411 1994
16
Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. 54 61
7510098 1994
17
Optic neuritis is associated with myelin basic protein and proteolipid protein reactive cells producing interferon-gamma, interleukin-4 and transforming growth factor-beta. 54 61
7507500 1994
18
Relative frequency of autoantibodies to myelin basic protein and proteolipid protein in optic neuritis and multiple sclerosis cerebrospinal fluid. 54 61
7510787 1994
19
Optic neuritis and multiple sclerosis: anti-MBP and anti-MBP peptide antibody-secreting cells are accumulated in CSF. 54 61
7513391 1993
20
T cells recognizing multiple peptides of myelin basic protein are found in blood and enriched in cerebrospinal fluid in optic neuritis and multiple sclerosis. 54 61
7680141 1993
21
Acute optic neuritis associated with immunization with the CNS myelin proteolipid protein. 54 61
1373123 1992
22
Bilateral retinal pathology following a first-ever clinical episode of autoimmune optic neuritis. 61
31969471 2020
23
Serum AQP4-IgG level is associated with the phenotype of the first attack in neuromyelitis optica spectrum disorders. 61
31986374 2020
24
Anti-myelin oligodendrocyte glycoprotein antibody associated disease spectrum - A north Indian tertiary care centre experience and review of literature. 61
31931436 2020
25
Influence of retinal NMDA receptor activity during autoimmune optic neuritis. 61
32031240 2020
26
MOG-IgG-associated demyelination: focus on atypical features, brain histopathology and concomitant autoimmunity. 61
31641876 2020
27
Collapsin Response-Mediator Protein 5-Associated Retinitis, Vitritis, and Optic Disc Edema. 61
31676123 2020
28
Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. 61
31743235 2020
29
VENOUS STASIS RETINOPATHY SECONDARY TO MYELIN-OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-POSITIVE OPTIC NEURITIS. 61
32015273 2020
30
A rare complication of combined oral contraceptives (COCs): optic neuritis. 61
32037928 2020
31
Clinical, imaging and follow-up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients. 61
31532865 2020
32
MIF -173G/C polymorphism is associated with NMO disease severity. 61
31790982 2020
33
Overlapping autoimmune syndrome: A case of concomitant anti-NMDAR encephalitis and myelin oligodendrocyte glycoprotein (MOG) antibody disease. 61
31837635 2020
34
CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease. 61
31582425 2020
35
Cognitive functions in Egyptian neuromyelitis optica spectrum disorder. 61
31790906 2020
36
Permanent visual work disabilities: 321 cases review. 61
32035740 2020
37
Neuromyelitis optica spectrum disorder coexisting with ankylosing spondylitis: A case report. 61
32036261 2020
38
Clinical findings and outcomes of uveitis associated with multiple sclerosis. 61
32019337 2020
39
Herpes viruses in optic neuritis: Similar to Bell's palsy. 61
31715425 2020
40
Acute changes in ganglion cell layer thickness in ischemic optic neuropathy compared to optic neuritis using optical coherence tomography. 61
31956579 2020
41
Gypenosides Prevent H2O2-Induced Retinal Ganglion Cell Apoptosis by Concurrently Suppressing the Neuronal Oxidative Stress and Inflammatory Response. 61
31897969 2020
42
Acute disseminated encephalomyelitis (ADEM) associated with mosquito-borne diseases: Chikungunya virus X yellow fever immunization. 61
31994659 2020
43
UNILATERAL OPTIC NEURITIS AND CENTRAL RETINAL VASCULITIS DUE TO OCULAR SYPHILIS. 61
28816862 2020
44
Diagnosis of Syphilitic Bilateral Papillitis Mimicking Papilloedema. 61
31855531 2020
45
Multimodal imaging patterns of posterior syphilitic uveitis: a review of the literature, laboratory evaluation and treatment. 61
31927680 2020
46
Toxocariasis of the Nervous System. 61
31960218 2020
47
Optic neuritis following anti-rabies vaccine. 61
31495273 2020
48
Optic neuritis in the era of biomarkers. 61
31425702 2020
49
Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence. 61
31740484 2020
50
Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. 61
31796527 2020

Variations for Optic Neuritis

ClinVar genetic disease variations for Optic Neuritis:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MT-ND4 NC_012920.1:m.11443A>CSNV Uncertain significance 523305 rs1556423952 MT:11443-11443 MT:11443-11443

Expression for Optic Neuritis

Search GEO for disease gene expression data for Optic Neuritis.

Pathways for Optic Neuritis

Pathways related to Optic Neuritis according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.57 TNF LTA IL10 CXCR3 CXCL8 CXCL10
2
Show member pathways
13.29 TNF LTA IL10 CXCR3 CXCL8 CXCL10
3
Show member pathways
13.22 TNF LTA IL10 HLA-DRB1 CXCL8 CXCL10
4
Show member pathways
13.14 TNF LTA IL10 CXCR3 CXCL8 CXCL10
5
Show member pathways
12.73 TNF LTA IL10 HLA-DRB1 CXCL8
6
Show member pathways
12.14 TNF IL10 HLA-DRB1 CCR5
7
Show member pathways
12.13 TNF LTA IL10 CXCL8 BDNF
8 11.94 TNF PLP1 IL10 CXCL8 BDNF AQP4
9
Show member pathways
11.83 TNF LTA IL10 CXCR3 CXCL8 CXCL10
10 11.66 TNF LTA IL10 CXCR3
11 11.64 TNF IL10 CXCL8
12 11.63 MOG GFAP CNTF BDNF
13 11.56 TNF IL10 CXCL10 BDNF
14 11.54 MBP MAG BDNF
15 11.42 TNF IL10 CXCL8
16 11.3 TNF MBP MAG GFAP CXCL8 CXCL10
17 11.24 TNF IL10 CXCL8 CXCL10 CCR5
18 11.13 TNF IL10 HLA-DRB1
19 10.82 TNF LTA IL10 GFAP CXCL8 CXCL10
20 10.4 PLP1 MBP MAG

GO Terms for Optic Neuritis

Cellular components related to Optic Neuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 compact myelin GO:0043218 9.26 MBP MAG
2 myelin sheath GO:0043209 9.26 PLP1 MPZ MBP MAG
3 external side of plasma membrane GO:0009897 9.17 TNF MOG HLA-DRB1 CXCR3 CXCL10 CCR5
4 astrocyte end-foot GO:0097450 9.16 GFAP AQP4

Biological processes related to Optic Neuritis according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.18 LTA IL10 DPYSL5 CXCR3 CXCL8 CXCL10
2 chemotaxis GO:0006935 9.81 CXCR3 CXCL8 CXCL10 CCR5
3 cell chemotaxis GO:0060326 9.79 CXCR3 CXCL10 CCR5
4 defense response GO:0006952 9.78 TNF CXCL8 CXCL10 CCR5
5 calcium-mediated signaling GO:0019722 9.76 CXCR3 CXCL8 CCR5
6 myelination GO:0042552 9.73 PLP1 MPZ MBP
7 cellular response to lipopolysaccharide GO:0071222 9.65 TNF IL10 CXCL8 CXCL10 CCR5
8 cytokine-mediated signaling pathway GO:0019221 9.63 TNF IL10 CXCL8 CXCL10 CNTF CCR5
9 chemokine-mediated signaling pathway GO:0070098 9.62 CXCR3 CXCL8 CXCL10 CCR5
10 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 9.61 MPZ MAG
11 T cell chemotaxis GO:0010818 9.6 CXCR3 CXCL10
12 response to molecule of bacterial origin GO:0002237 9.59 IL10 CXCL8
13 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.58 MBP IL10
14 leukocyte chemotaxis GO:0030595 9.58 IL10 CXCL8 CXCL10
15 endothelial cell apoptotic process GO:0072577 9.57 TNF IL10
16 axon ensheathment GO:0008366 9.55 PLP1 MBP
17 negative regulation of cytokine secretion involved in immune response GO:0002740 9.54 TNF IL10
18 positive regulation of glial cell proliferation GO:0060252 9.54 TNF LTA GFAP
19 inflammatory response GO:0006954 9.5 TNF PLP1 IL10 CXCR3 CXCL8 CXCL10
20 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.49 TNF LTA
21 receptor biosynthetic process GO:0032800 9.46 TNF IL10
22 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.43 TNF LTA
23 immune response GO:0006955 9.28 TNF MBP LTA IL10 HLA-DRB1 CXCR3

Molecular functions related to Optic Neuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.33 MOG HLA-DRB1 CCR5
2 cytokine activity GO:0005125 9.1 TNF LTA IL10 CXCL8 CXCL10 CNTF
3 structural constituent of myelin sheath GO:0019911 8.96 PLP1 MBP

Sources for Optic Neuritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....